(PDF) Pmu28 - A Cross Indication Budget Impact Analysis of

Pmu28 - A Cross Indication Budget Impact Analysis of Secukinumab: A Greek Perspective

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.1864

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

October 1, 2018

Authors

M Kalogeropoulou

Publisher

Elsevier BV

Related search

Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis: A Canadian Perspective

Value in Health

Occupational Health

English

Budget Impact Analysis of Balloon Dilation and Functional Endoscopic Surgery – A Us Payer Perspective

Value in Health

Occupational Health

English

Pms20 - Budget Impact of Introducing Secukinumab in the Treatment of Ankylosing Spondylitis From the Private Payer Perspective in Brazil

Value in Health

Occupational Health

English

Budget Impact Analysis of PCSK9 Inhibitors Costs From a Community Payers’ Perspective in Apulia, Italy

Cardiovascular Medicine

English

Psy50 - Budget-Impact Analysis (Bia) of Chronic Pain Syndromes From a Healthcare Payer Perspective in Brazil

Value in Health

Occupational Health

English

Pcv43 - Budget Impact Analysis of the Introduction of a Single-Pill Combination of Atorvastatin, Perindopril and Amlodipine in the Greek Setting

Value in Health

Occupational Health

English

Budget Impact Analysis of Cementless Versus Cemented Prostheses for Total HIP Arthroplasty From a UK Hospital Perspective

Value in Health

Occupational Health

English

Budget Impact Analysis of Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer From a u.s. Payer Perspective

Value in Health

Occupational Health

English

A Budget Impact Analysis of Adalimumab Biosimilar: The Italian Context

English